Elenagen, a novel DNA immunotherapy for ovarian cancer, found to delay disease progression
CureLab Oncology, a clinical-stage, pre-IPO biotech company, announced that its novel biological agent, Elenagen, has been shown to significantly enhance standard chemotherapy and provides clinical benefits for the patients ...
Feb 22, 2024
0
0